0001415889-24-010509.txt : 20240408
0001415889-24-010509.hdr.sgml : 20240408
20240408172025
ACCESSION NUMBER: 0001415889-24-010509
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240404
FILED AS OF DATE: 20240408
DATE AS OF CHANGE: 20240408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ragosa Mark
CENTRAL INDEX KEY: 0001835458
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38492
FILM NUMBER: 24830499
MAIL ADDRESS:
STREET 1: C/O KINIKSA PHARMACEUTICALS CORP.
STREET 2: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd.
CENTRAL INDEX KEY: 0001730430
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
BUSINESS PHONE: 7814399100
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
4
1
form4-04082024_090417.xml
X0508
4
2024-04-04
0001730430
Kiniksa Pharmaceuticals, Ltd.
KNSA
0001835458
Ragosa Mark
C/O KINIKSA PHARMACEUTICALS, LTD.
CLARENDON HOUSE 2 CHURCH STREET
HAMILTON
D0
HM 11
BERMUDA
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Class A Common Share
2024-04-08
4
M
0
2694
A
19562
D
Class A Common Share
2024-04-08
4
F
0
791
17.90
D
18771
D
Share Option
18.06
2024-04-04
4
A
0
33150
0
A
2034-03-31
Class A Common Share
33150
33150
D
Performance Share Unit
2024-04-04
4
A
0
5092
0
A
2034-03-31
Class A Common Share
5092
5092
D
Restricted Share Unit
2024-04-04
4
A
0
6365
0
A
Class A Common Share
6365
11615
D
Restricted Share Unit
2024-04-08
4
M
0
2694
0
D
Class A Common Share
2694
8921
D
Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.
Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply.
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date April 1, 2024.
The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.
/s/ Madelyn Zeylikman, Attorney-in-Fact
2024-04-08